{"title":"The first attempt in synthesis, identification, and evaluation of SEPT9 inhibitors on human oral squamous carcinomas.","authors":"Hsuan-Yu Lai, Ko-Hua Yu, Keng-Chang Tsai, Chao-Chang Lee, Han-Yu Wang, Yi-Ping Hsieh, Kuan-Yi Chiang, Pao-Lin Kuo, Tze-Ta Huang, Hsin-Yi Hung","doi":"10.1016/j.bioorg.2024.108068","DOIUrl":null,"url":null,"abstract":"<p><p>Septin 9 (SEPT9), a GTPase, known as the fourth cytoskeleton, is widely expressed in various cells and tissues. The functions of SEPT9 are partly similar to other cytoskeletons as a structure protein. Further, SEPT9 can interact with other cytoskeletons, participating in actin dynamics and microtubule regulation. SEPT9 is associated with various diseases, such as cancers. Thus, it could be a potential drug target. However, there are no small molecule SEPT9 inhibitors and the only reported septin inhibitor, forchlorfenuron, has no effects on SEPT9 inhibition from our study results. Therefore, the derivatives of forchlorfenuron were synthesized, and their activities were evaluated by a direct SEPT9 inhibition screening platform, followed by localized surface plasmon resonance (LSPR) and cell-based assays. The screening results conveyed that 6b, 8a, and 8b are SEPT9 inhibitors with IC<sub>50</sub> values of 91, 99, and 95 μM, respectively. Also, their binding affinities were 4, 18, and 22 μM, respectively, validated through LSPR. Eventually, the SAR concludes that at the para position, small substituents are tolerated, while at the ortho position, a bulky benzene ring substituent can be the best candidate. In cell-based assays, the IC<sub>50</sub> of 6a, 8a, and 8b of human oral squamous carcinomas cytotoxicity were 122, 20, and 21 µM, respectively. Additionally, significant suppression of the cell migration and invasion ability was observed with the 8b treatment. The co-localization study revealed that 8b effectively disrupted the structural organization of SEPT9, microtubules, and actins. This is the first article to systematically study SEPT9 inhibitors and their biological properties, hoping to shed some light on septin research.</p>","PeriodicalId":257,"journal":{"name":"Bioorganic Chemistry","volume":"154 ","pages":"108068"},"PeriodicalIF":4.5000,"publicationDate":"2024-12-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Bioorganic Chemistry","FirstCategoryId":"92","ListUrlMain":"https://doi.org/10.1016/j.bioorg.2024.108068","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Septin 9 (SEPT9), a GTPase, known as the fourth cytoskeleton, is widely expressed in various cells and tissues. The functions of SEPT9 are partly similar to other cytoskeletons as a structure protein. Further, SEPT9 can interact with other cytoskeletons, participating in actin dynamics and microtubule regulation. SEPT9 is associated with various diseases, such as cancers. Thus, it could be a potential drug target. However, there are no small molecule SEPT9 inhibitors and the only reported septin inhibitor, forchlorfenuron, has no effects on SEPT9 inhibition from our study results. Therefore, the derivatives of forchlorfenuron were synthesized, and their activities were evaluated by a direct SEPT9 inhibition screening platform, followed by localized surface plasmon resonance (LSPR) and cell-based assays. The screening results conveyed that 6b, 8a, and 8b are SEPT9 inhibitors with IC50 values of 91, 99, and 95 μM, respectively. Also, their binding affinities were 4, 18, and 22 μM, respectively, validated through LSPR. Eventually, the SAR concludes that at the para position, small substituents are tolerated, while at the ortho position, a bulky benzene ring substituent can be the best candidate. In cell-based assays, the IC50 of 6a, 8a, and 8b of human oral squamous carcinomas cytotoxicity were 122, 20, and 21 µM, respectively. Additionally, significant suppression of the cell migration and invasion ability was observed with the 8b treatment. The co-localization study revealed that 8b effectively disrupted the structural organization of SEPT9, microtubules, and actins. This is the first article to systematically study SEPT9 inhibitors and their biological properties, hoping to shed some light on septin research.
期刊介绍:
Bioorganic Chemistry publishes research that addresses biological questions at the molecular level, using organic chemistry and principles of physical organic chemistry. The scope of the journal covers a range of topics at the organic chemistry-biology interface, including: enzyme catalysis, biotransformation and enzyme inhibition; nucleic acids chemistry; medicinal chemistry; natural product chemistry, natural product synthesis and natural product biosynthesis; antimicrobial agents; lipid and peptide chemistry; biophysical chemistry; biological probes; bio-orthogonal chemistry and biomimetic chemistry.
For manuscripts dealing with synthetic bioactive compounds, the Journal requires that the molecular target of the compounds described must be known, and must be demonstrated experimentally in the manuscript. For studies involving natural products, if the molecular target is unknown, some data beyond simple cell-based toxicity studies to provide insight into the mechanism of action is required. Studies supported by molecular docking are welcome, but must be supported by experimental data. The Journal does not consider manuscripts that are purely theoretical or computational in nature.
The Journal publishes regular articles, short communications and reviews. Reviews are normally invited by Editors or Editorial Board members. Authors of unsolicited reviews should first contact an Editor or Editorial Board member to determine whether the proposed article is within the scope of the Journal.